Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program

被引：0

作者：

Warren, Richard B. ^{[1
]}

Armstrong, April W. ^{[2
]}

Imafuku, Shinichi ^{[3
]}

Paul, Carle ^{[4
,5
]}

Kircik, Leon ^{[6
]}

Colston, Elizabeth ^{[7
]}

Scharnitz, Thomas ^{[7
]}

Wang, Tao ^{[7
]}

Banerjee, Subhashis ^{[7
]}

Strober, Bruce ^{[8
,9
]}

机构：

[1] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Salford, Lancs, England

[2] Univ Southern Calif, Los Angeles, CA USA

[3] Fukuoka Univ Hosp, Fukuoka, Japan

[4] Univ Toulouse, Toulouse, France

[5] CHU, Toulouse, France

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Bristol Myers Squibb, New York, NY USA

[8] Yale Univ, Sch Med, New Haven, CT USA

[9] Cent Connecticut Dermatol Res, Cromwell, CT USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43879

引用

页码：AB147 / AB147

页数：1

共 50 条

[1] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Gooderham, Melinda
Spelman, Lynda
Imafuku, Shinichi
Romanelli, Marco
Merola, Joseph F.
Armstrong, April W.
Colston, Elizabeth
Banerjee, Subhashis
Scharnitz, Thomas
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[2] DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MODERATE TO SEVERE PLAQUE PSORIASIS: 52-WEEK EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 TRIALS
Warren, R. B.
Armstrong, A.
Gooderham, M.
Strober, B.
Thaci, D.
Imafuku, S.
Sofen, H.
Spelman, L.
Korman, N. J.
Zheng, M.
Colston, E.
Throup, J.
Kundu, S.
Kisa, R.
Banerjee, S.
Blauvelt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1570 - 1571
[3] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
Spelman, Lynda
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66
[4] DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Korman, N. J.
Passeron, T.
Gordon, K. B.
Okubo, Y.
Bagel, J.
Sofen, H.
Warren, R. B.
Bhatia, N.
Spelman, L.
Winthrop, K.
Hippeli, L.
Kisa, R. M.
Banerjee, S.
Thaci, D.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1774 - 1775
[5] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trials
Foley, Peter
Zhang, Jianzhong
Imafuku, Shinichi
Ding, Yangfeng
Okubo, Yukari
Li, Hui
Tada, Yayoi
Li, Linfeng
Ohtsuki, Mamitaro
Pan, Weili
Lu, Yan
Hao, Cheng
Xian, Jiang
Ho, Ji-Chen
Guo, Shuping
Seo, Seong Jun
Napoli, Andrew
Chatterjee, Arkendu
Kisa, Renata M.
Banerjee, Subhashis
Morita, Akimichi
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 29
[6] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Improvement in body surface area involvement in the phase 3 POETYK PSO-3 trial
Zhang, J.
Ding, Y.
Wang, P.
Li, L.
Pan, W.
Lu, Y.
Liu, L.
Kisa, R. M.
Hoyt, K.
Banerjee, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S109 - S109
[7] Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
Galluzzo, Marco
Vellucci, Laura
Marcelli, Lorenzo
Paganini, Claudia
Bianchi, Luca
Talamonti, Marina
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (09) : 981 - 988
[8] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor: Improvement in scalp psoriasis in the phase 3 POETYK PSO-3 trial in Asian patients
Zhang, J.
Ding, Y.
Wang, P.
Li, L.
Pan, W.
Lu, Y.
Liu, L.
Kisa, R. M.
Hoyt, K.
Banerjee, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S108 - S108
[9] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
Armstrong, A.
Gooderham, M.
Warren, R. B.
Papp, K.
Strober, B.
Thaci, D.
Colston, E.
Throup, J.
Kundu, S.
Banerjee, S.
Blauvelt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 795 - 796
[10] Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
Spelman, Lynda
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Blauvelt, Andrew
Toms, Jessica
Buck, Alex
Banerjee, Subhashis
Menter, Alan
Szepietowski, Jacek C.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 28

← 1 2 3 4 5 →